Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Fourteen elderly patients (median age 85 years) who were considered non-candidates for R-CHOP were treated first-line with a combination of bendamustine and rituximab. Of these, 7 achieved a complete response and 2 achieved a partial response. Toxicity was minimal. Although promising, these results need to be confirmed in larger studies.

Bendamustine-Rituximab as First-line Treatment for NHL Patients Over the Age of 80 Years